Role of Cannabinoid Receptors in Anxiety Disorders

  • Aldemar Degroot

Cannabinoid agents modulate anxiety, although their effects vary and depend on regional endogenous tone, basal anxiety levels, environmental context, species differences, type of anxiety, prior exposure, and dose. Cannabinoid receptors are densely located in brain areas that are involved in the regulation of emotional states and induce neurochemical responses that are congruent with anxiolyt ic/anxiogenic effects. The effects on emotion mediated by cannabinoid compounds are believed to be due to a regulation of activity at the cannabinoid CB1 receptors although there is some limited evidence implicating the cannabinoid CB2 and a putative novel cannabinoid receptor (GPR55?) in some of the observed emotional responses. Effects on emotion are likely the result of a net effect of the summated neurochemical responses. Compounds that indirectly regulate activity at the cannabinoid receptors more consistently reduce anxiety both in preclinical and clinical models. Consequently, these compounds may be the focus of future pharmaceutical development of anxiolytic compounds.


Anxiety Disorder Anxiolytic Effect Anxiogenic Effect FAAH Inhibitor Nabinoid Receptor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Azad SC, Monory K, Marsicano G, Cravatt BF, Lutz B, Zieglgansberger W, Rammes G (2004) Circuitry for associative plasticity in the amygdala involves endocannabinoid signaling. J Neurosci 24:9953–9961.CrossRefPubMedGoogle Scholar
  2. Bari M, Battista N, Fezza F, Gasperi V, Maccarrone M (2006) New insights into endocannabinoid degradation and its therapeutic potential. Mini Rev Med Chem 6:257–268.CrossRefPubMedGoogle Scholar
  3. Berrendero F, Maldonado R (2002) Involvement of the opioid system in the anxiolytic-like effects induced by Delta9-tetrahydrocannabinol. Psychopharmacology 163:111–117.CrossRefPubMedGoogle Scholar
  4. Biscaia M, Marin S, Fernandez B, Marco EM, Rubio M, Guaza C, Ambrosio E, Viveros MP (2003) Chronic treatment with CP 55, 940 during the peri-adolescent period differentially affects the behavioural responses of male and female rats in adulthood. Psychopharmacology 170:301–308.CrossRefPubMedGoogle Scholar
  5. Braida D, Limonta V, Malabarba L, Zani A, Sala M (2007) 5-HT1A receptors are involved in the anxiolytic effect of Delta9-tetrahydrocannabinol and AM 404, the anandamide transport inhibitor, in Sprague-Dawley rats. Eur J Pharmacol 555:156–163.CrossRefPubMedGoogle Scholar
  6. Chhatwal JP, Davis M, Maguschak KA, Ressler KJ (2005) Enhancing cannabinoid neurotransmission augments the extinction of conditioned fear. Neuropsychopharmacology 30:516–524.CrossRefPubMedGoogle Scholar
  7. Crippa JA, Zuardi AW, Garrido GE, Wichert-Ana L, Guarnieri R, Ferrari L, Azevedo-Marques PM, Hallak JE, McGuire PK, Filho Busatto G (2004) Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology 29:417–426.CrossRefPubMedGoogle Scholar
  8. Degroot A, Nomikos GG (2004) Genetic deletion and pharmacological blockade of CB1 receptors modulates anxiety in the shock-probe burying test. Eur J Neurosci 20:1059–1064.CrossRefPubMedGoogle Scholar
  9. Degroot A, Nomikos GG (2005) Fluoxetine disrupts the integration of anxiety and aversive memories. Neuropsychopharmacology 30:391–400.CrossRefPubMedGoogle Scholar
  10. Degroot A, Nomikos GG (2007) In vivo neurochemical effects induced by changes in endocannabinoid neurotransmission. Curr Opin Pharmacol 7:62–68.CrossRefPubMedGoogle Scholar
  11. Degroot A, Treit D (2002) Dorsal and ventral hippocampal cholinergic systems modulate anxiety in the plus-maze and shock-probe tests. Brain Res 949:60–70.CrossRefPubMedGoogle Scholar
  12. Degroot A, Köfalvi A, Wade MR, Davis RJ, Rodrigues RJ, Rebola N, Cunha RA, Nomikos GG (2006) CB1 receptor antagonism increases hippocampal acetylcholine release: site and mechanism of action. Mol Pharmacol 70:1236–1245.CrossRefPubMedGoogle Scholar
  13. Dekeyne A, Brocco M, Adhumeau A, Gobert A, Millan MJ (2000) The selective serotonin (5-HT)1A receptor ligand, S15535, displays anxiolytic-like effects in the social interaction and Vogel models and suppresses dialysate levels of 5-HT in the dorsal hippocampus of freely-moving rats. A comparison with other anxiolytic agents. Psychopharmacology 152:55–66.CrossRefPubMedGoogle Scholar
  14. Gaetani S, Cuomo V, Piomelli D (2003) Anandamide hydrolysis: a new target for anti-anxiety drugs? Trends Mol Med 9:474–478.CrossRefPubMedGoogle Scholar
  15. Genn RF, Tucci S, Marco EM, Viveros MP, File SE (2004) Unconditioned and conditioned anxiogenic effects of the cannabinoid receptor agonist CP 55, 940 in the social interaction test. Pharmacol Biochem Behav 77:567–573.CrossRefPubMedGoogle Scholar
  16. Giuliani D, Ferrari F, Ottani A (2000) The cannabinoid agonist HU 210 modifies rat behavioural responses to novelty and stress. Pharmacol Res 41:45–51.CrossRefPubMedGoogle Scholar
  17. Gregg JM, Small EW, Moore R, Raft D, Toomey TC (1976) Emotional response to intravenous delta9tetrahydrocannabinol during oral surgery. J Oral Surg 34:301–313.PubMedGoogle Scholar
  18. Griebel G, Stemmelin J, Scatton B (2005) Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biol Psychiatry 57:261–267.CrossRefPubMedGoogle Scholar
  19. Guimaraes FS, Chiaretti TM, Graeff FG, Zuardi AW (1990) Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology 100:558–559.CrossRefPubMedGoogle Scholar
  20. Guimaraes FS, de Aguiar JC, Mechoulam R, Breuer A (1994) Anxiolytic effect of cannabidiol derivatives in the elevated plus-maze. Gen Pharmacol 25:161–164.PubMedGoogle Scholar
  21. Gunnell D, Saperia J, Ashby D (2005) Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA’s safety review. BMJ 330:385.CrossRefPubMedGoogle Scholar
  22. Haller J, Bakos N, Szirmay M, Ledent C, Freund TF (2002) The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur J Neurosci 16:1395–1398.CrossRefPubMedGoogle Scholar
  23. Haller J, Varga B, Ledent C, Freund TF (2004) CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents. Behav Pharmacol 15:299–304.CrossRefPubMedGoogle Scholar
  24. Haller J, Soproni K, Varga B, Nemeth B, Mikics E, Freund TF, Matyas F, Hajos N (2006) Correlated species differences in the effects of cannabinoid ligands on anxiety and on GABAergic/glutamatergic synaptic transmission. Sixteenth Annual Symposium on the Cannabinoids, ICRS, Tihany, Hungary.Google Scholar
  25. Hill MN, Gorzalka BB (2004) Enhancement of anxiety-like responsiveness to the cannabinoid CB1 receptor agonist HU-210 following chronic stress. Eur J Pharmacol 499:291–295.CrossRefPubMedGoogle Scholar
  26. Hill MN, Gorzalka BB (2006) Increased sensitivity to restraint stress and novelty-induced emotionality following long-term, high dose cannabinoid exposure. Psychoneuroendocrinology 31:526–536.CrossRefPubMedGoogle Scholar
  27. Howlett AC (2005) Cannabinoid receptor signaling. Handb Exp Pharmacol 168:53–79.CrossRefPubMedGoogle Scholar
  28. Jiang W, Zhang Y, Xiao L, Van Cleemput J, Ji SP, Bai G, Zhang X (2005) Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. J Clin Invest 115:3104–3116.CrossRefPubMedGoogle Scholar
  29. Jung KM, Mangieri R, Stapleton C, Kim J, Fegley D, Wallace M, Mackie K, Piomelli D (2005) Stimulation of endocannabinoid formation in brain slice cultures through activation of group I metabotropic glutamate receptors. Mol Pharmacol 68:1196–1202.CrossRefPubMedGoogle Scholar
  30. Kataoka Y, Shibata K, Miyazaki A, Inoue Y, Tominaga K, Koizumi S, Ueki S, Niwa M (1991) Involvement of the dorsal hippocampus in mediation of the antianxiety action of tandospirone, a 5-hydroxytryptamine1A agonistic anxiolytic. Neuropharmacology 30:475–480.CrossRefPubMedGoogle Scholar
  31. Kreitzer AC, Malenka RC (2005) Dopamine modulation of state-dependent endocannabinoid release and long-term depression in the striatum. J Neurosci 25:10537–10545.CrossRefPubMedGoogle Scholar
  32. MacLean KI, Littleton JM (1977) Environmental stress as a factor in the response of rat brain catecholamine metabolism to delta8-tetrahydrocannabinol. Eur J Pharmacol 41:171–182.CrossRefPubMedGoogle Scholar
  33. Maejima T, Oka S, Hashimotodani Y, Ohno-Shosaku T, Aiba A, Wu D, Waku K, Sugiura T, Kano M (2005) Synaptically driven endocannabinoid release requires Ca2+-assisted metabotropic glutamate receptor subtype 1 to phospholipase Cbeta4 signaling cascade in the cerebellum. J Neurosci 25:6826–6835.CrossRefPubMedGoogle Scholar
  34. Manzanares J, Corchero J, Fuentes JA (1999) Opioid and cannabinoid receptor-mediated regulation of the increase in adrenocorticotropin hormone and corticosterone plasma concentrations induced by central administration of delta9-tetrahydrocannabinol in rats. Brain Res 839:173–179.CrossRefPubMedGoogle Scholar
  35. Marco EM, Perez-Alvarez L, Borcel E, Rubio M, Guaza C, Ambrosio E, File SE, Viveros MP (2004) Involvement of 5-HT1A receptors in behavioural effects of the cannabinoid receptor agonist CP 55, 940 in male rats. Behav Pharmacol 15:21–27.CrossRefPubMedGoogle Scholar
  36. Marin S, Marco E, Biscaia M, Fernandez B, Rubio M, Guaza C, Schmidhammer H, Viveros MP (2003) Involvement of the kappa-opioid receptor in the anxiogenic-like effect of CP 55, 940 in male rats. Pharmacol Biochem Behav 74:649–656.CrossRefPubMedGoogle Scholar
  37. Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, Hermann H, Tang J, Hofmann C, Zieglgansberger W, Di Marzo V, Lutz B (2002) The endogenous cannabinoid system controls extinction of aversive memories. Nature 418:530–534.CrossRefPubMedGoogle Scholar
  38. Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O (2002) Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology (Berl) 159:379–387.CrossRefGoogle Scholar
  39. Meneses A, Hong E (1993) Modification of the anxiolytic effects of 5-HT1A agonists by shock intensity. Pharmacol Biochem Behav 46:569–573.CrossRefPubMedGoogle Scholar
  40. Millan MJ (2003) The neurobiology and control of anxious states. Prog Neurobiol 70:83–244.CrossRefPubMedGoogle Scholar
  41. Moreira FA, Aguiar DC, Guimaraes FS (2006) Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test. Prog Neuropsychopharmacol Biol Psychiatry 30:1466–1471.CrossRefPubMedGoogle Scholar
  42. Musty R (1984) Possible anxiolytic effects of cannabidiol. In: Agurell S, Dewey WL, Willette RE (eds.), The Cannabinoids: Chemical, Pharmacological and Therapeutic Aspects. New York: Academic Press, pp. 795–813.Google Scholar
  43. Musty R, Conti LH, Mechoulam R (1984) Anxiolytic properties of cannabidiol. In: Harvey DJ (ed.), Marihuana 84: Proceedings of the Oxford Symposium on Cannabis. Oxford: IRL Press, pp. 713–719.Google Scholar
  44. Nadulski T, Sporkert F, Schnelle M, Stadelmann AM, Roser P, Schefter T, Pragst F (2005) Simultaneous and sensitive analysis of THC, 11-OH-THC, THC-COOH, CBD, and CBN by GC-MS in plasma after oral application of small doses of THC and cannabis extract. J Anal Toxicol 29:782–789.PubMedGoogle Scholar
  45. Naliboff BD, Rickles WH, Cohen MJ, Naimark RS (1976) Interactions of marijuana and induced stress: forearm blood flow, heart rate, and skin conductance. Psychophysiology 13:517–522.CrossRefPubMedGoogle Scholar
  46. Navarro M, Hernandez E, Munoz RM, del Arco I, Villanua MA, Carrera MR, Rodriguez de Fonseca F (1997) Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. Neuroreport 8:491–496.CrossRefPubMedGoogle Scholar
  47. Ng LK, Lamprecht F, Williams RB, Kopin IJ (1973) Delta9-tetrahydrocannabinol and ethanol: differential effects on sympathetic activity in differing environmental setting. Science 180:1368–1369.CrossRefPubMedGoogle Scholar
  48. Onaivi ES (2006) Neuropsychobiological evidence for the functional presence and expression of cannabinoid CB2 receptors in the brain. Neuropsychobiology 54:231–246.CrossRefPubMedGoogle Scholar
  49. Onaivi ES, Green MR, Martin BR (1990) Pharmacological characterization of cannabinoids in the elevated plus maze. J Pharmacol Exp Ther 253:1002–1009.PubMedGoogle Scholar
  50. Pamplona FA, Prediger RD, Pandolfo P, Takahashi RN (2006) The cannabinoid receptor agonist WIN 55, 212–2 facilitates the extinction of contextual fear memory and spatial memory in rats. Psychopharmacology 188:641–649.CrossRefPubMedGoogle Scholar
  51. Patel S, Hillard CJ (2006) Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. J Pharmacol Exp Ther 318:304–311.CrossRefPubMedGoogle Scholar
  52. Patel S, Roelke CT, Rademacher DJ, Cullinan WE, Hillard CJ (2004) Endocannabinoid signaling negatively modulates stress-induced activation of the hypothalamic-pituitary-adrenal axis. Endocrinology 145:5431–5438.CrossRefPubMedGoogle Scholar
  53. Patel S, Cravatt BF, Hillard CJ (2005) Synergistic interactions between cannabinoids and environmental stress in the activation of the central amygdala. Neuropsychopharmacology 30:497–507.CrossRefPubMedGoogle Scholar
  54. Pertwee RG (1997) Pharmacological of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 74:129–180.CrossRefPubMedGoogle Scholar
  55. Pertwee RG (2005) Pharmacological actions of cannabinoids. Handb Exp Pharmacol 168:1–51.CrossRefPubMedGoogle Scholar
  56. Petitet F, Donlan M, Michel A (2006) GPR55 as a new cannabinoid receptor: still a long way to prove it. Chem Biol Drug Des 67:252–253.CrossRefPubMedGoogle Scholar
  57. Piomelli D, Tarzia G, Duranti A, Tontini A, Mor M, Compton TR, Dasse O, Monaghan EP, Parrott JA, Putman D (2006) Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). CNS Drug Rev 12:21–38.CrossRefPubMedGoogle Scholar
  58. Rakhshan F, Day TA, Blakely RD, Barker EL (2000) Carrier-mediated uptake of the endogenous cannabinoid anandamide in RBL-2H3 cells. J Pharmacol Exp Ther 292:960–967.PubMedGoogle Scholar
  59. Resstel LB, Joca SR, Moreira FA, Correa FM, Guimaraes FS (2006) Effects of cannabidiol and diazepam on behavioral and cardiovascular responses induced by contextual conditioned fear in rats. Behav Brain Res 172:294–298.CrossRefPubMedGoogle Scholar
  60. Rimonabant. New Drug Evaluation. Regional Drug & Therapeutic Centre (November 2006): No 78. Available at
  61. Rodgers RJ, Haller J, Halasz J, Mikics E (2003) ‘One-trial sensitization’ to the anxiolytic-like effects of cannabinoid receptor antagonist SR141716A in the mouse elevated plus-maze. Eur J Neurosci 17:1279–1286.CrossRefPubMedGoogle Scholar
  62. Rodgers RJ, Evans PM, Murphy A (2005) Anxiogenic profile of AM-251, a selective cannabinoid CB1 receptor antagonist, in plus-maze-naive and plus-maze-experienced mice. Behav Pharmacol 16:405–413.CrossRefPubMedGoogle Scholar
  63. Rodriguez de Fonseca F, Rubio P, Menzaghi F, Merlo-Pich E, Rivier J, Koob GF, Navarro M (1996) Corticotropin-releasing factor (CRF) antagonist [D-Phe12, Nle21, 38, C alpha MeLeu37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats. J Pharmacol Exp Ther 276:56–64.PubMedGoogle Scholar
  64. Rubino T, Sala M, Vigano D, Braida D, Castiglioni C, Limonta V, Guidali C, Realini N, Parolaro D (2007) Cellular mechanisms underlying the anxiolytic effect of low doses of peripheral delta9-tetrahydrocannabinol in rats. Neuropsychopharmacology 32:2036–2045.CrossRefPubMedGoogle Scholar
  65. Russo EB, Burnett A, Hall B, Parker KK (2005) Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res 30:1037–1043.CrossRefPubMedGoogle Scholar
  66. Rutkowska M, Jamontt J, Gliniak H (2006) Effects of cannabinoids on the anxiety-like response in mice. Pharmacol Rep 58:200–206.PubMedGoogle Scholar
  67. Schneider M, Drews E, Koch M (2005) Behavioral effects in adult rats of chronic prepubertal treatment with the cannabinoid receptor agonist WIN 55, 212–2. Behav Pharmacol 16:447–454.CrossRefPubMedGoogle Scholar
  68. Takahashi RN, Pamplona FA, Fernandes MS (2005) The cannabinoid antagonist SR141716A facilitates memory acquisition and consolidation in the mouse elevated T-maze. Neurosci Lett 380:270–275.CrossRefPubMedGoogle Scholar
  69. Tzavara ET, Wade M, Nomikos GG (2003) Biphasic effects of cannabinoids on acetylcholine release in the hippocampus: site and mechanism of action. J Neurosci 23:9374–9384.PubMedGoogle Scholar
  70. Uriguen L, Perez-Rial S, Ledent C, Palomo T, Manzanares J (2004) Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors. Neuropharmacology 46:966–973.CrossRefPubMedGoogle Scholar
  71. Viveros MP, Marco EM, File SE (2005) Endocannabinoid system and stress and anxiety responses. Pharmacol Biochem Behav 81:331–342.CrossRefPubMedGoogle Scholar
  72. Watanabe K, Kayano Y, Matsunaga T, Yamamoto I, Yoshimura H (1996) Inhibition of anandamide amidase activity in mouse brain microsomes by cannabinoids. Biol Pharm Bull 19:1109–1111.PubMedGoogle Scholar
  73. Weiser M, Noy S (2005) Interpreting the association between cannabis use and increased risk for schizophrenia. Dialogues Clin Neurosci 7:81–85.PubMedGoogle Scholar
  74. Witkin JM, Tzavara ET, Nomikos GG (2005) A role for cannabinoid CB1 receptors in mood and anxiety disorders. Behav Pharmacol 16:315–331.CrossRefPubMedGoogle Scholar
  75. Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG (1982) Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology 76:245–250.CrossRefPubMedGoogle Scholar
  76. Zuardi AW, Cosme RA, Graeff FG, Guimareas FS (1993a) Effects of ipsapirone and cannabidiol on human experimental anxiety. J Psychopharmacol 7:82–88.Google Scholar
  77. Zuardi AW, Guimaraes FS, Moreira AC (1993b) Effect of cannabidiol on plasma prolactin, growth hormone and cortisol in human volunteers. Braz J Med Biol Res 26:213–217.PubMedGoogle Scholar

Copyright information

© Springer 2008

Authors and Affiliations

  • Aldemar Degroot
    • 1
  1. 1.Astellas Pharma Europe B.V., Elisabethhof 1The Netherlands

Personalised recommendations